Burton Liebross, MD
Nephrology · Tarzana, CANPI 1659350718
Payments from drug & device makers
Across 175 payments — averaging $31.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Amgen$726
- AstraZeneca$335
- AbbVie$333
- Abbott$305
- Pfizer$218
- plus $2K from 33 others
What the payments were for
- Consulting fees$1,20022%
- Travel & lodging$511%
- Food & beverage$4,23176%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 4 | $1,394 |
| Amgen(2 entities) | 31 | $726 |
| AstraZeneca(2 entities) | 17 | $335 |
| AbbVie | 9 | $333 |
| Abbott | 3 | $305 |
| Pfizer | 11 | $218 |
| GSK | 7 | $186 |
| Daiichi Sankyo Inc. | 8 | $175 |
| Amarin Pharma, Inc. | 9 | $174 |
| Merck | 10 | $160 |
| Otsuka America Pharmaceutical, Inc. | 6 | $145 |
| Bayer | 5 | $130 |
| Intuitive Surgical | 1 | $115 |
| Novartis | 4 | $114 |
| Lilly USA, LLC | 5 | $102 |
| Novo Nordisk | 5 | $97 |
| Sanofi | 1 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $66 |
| Boehringer Ingelheim | 3 | $65 |
| Genentech, Inc. | 2 | $63 |
| Eisai Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $54 |
| Radius Health, Inc. | 2 | $43 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Nevro Corp. | 1 | $35 |
| Exact Sciences | 2 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Vertiflex, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,321
- PROCLAIM$280
- UBRELVY$125
- Da Vinci Surgical System$115
How this compares
$5,580 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $145,707 |
| JardianceEmpagliflozin | 88 | $118,704 |
| FarxigaDapagliflozin Propanediol | 85 | $103,601 |
| EliquisApixaban | 81 | $98,873 |
| Repatha SureclickEvolocumab | 91 | $85,297 |
| MounjaroTirzepatide | 47 | $67,525 |
| Nurtec OdtRimegepant Sulfate | 30 | $46,441 |
| EntrestoSacubitril/Valsartan | 23 | $42,157 |
| XareltoRivaroxaban | 26 | $31,588 |
| RybelsusSemaglutide | 18 | $28,203 |
| WegovySemaglutide | 15 | $24,549 |
| TrulicityDulaglutide | 15 | $23,697 |
| JanuviaSitagliptin Phosphate | 24 | $21,288 |
| Spiriva RespimatTiotropium Bromide | 12 | $15,759 |
| KerendiaFinerenone | 17 | $15,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $97 | $198,459140 claims |
| PfizerEliquis, Nurtec Odt | $218 | $145,314111 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $65 | $134,463100 claims |
| AstraZenecaFarxiga | $335 | $103,60185 claims |
| Lilly USA, LLCMounjaro, Trulicity | $102 | $91,22262 claims |
| NovartisEntresto | $114 | $42,15723 claims |
| MerckJanuvia | $160 | $21,28824 claims |
| BayerKerendia | $130 | $15,62517 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $82 | $9,48118 claims |
| AbbVieSynthroid | $333 | $5,29386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.
Other nephrology in Tarzana
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.